SI
SI
discoversearch

Biotech / Medical
MGNX -- MacroGenics
An SI Board Since November 2013
Posts SubjectMarks Bans Symbol
89 27 0 MGNX
Emcee:  scaram(o)uche Type:  Moderated
CD123-related abstract (preclinical) coming up at ASH, so maybe it's time for a thread. DART is a very old concept.... I was one of the first to try it, but the original concept came from Dartmouth and served as the foundation science for Medarex.

MGD006, Servier has right to license for some geographies.....

ash.confex.com

One more ASH abstract, not from MGNX.......

ash.confex.com

Pointer to the pipeline chart, website.....

macrogenics.com

Go!
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
89Great, at least they may not follow HALO (or PBYI) steps/path!Miljenko Zuanic-January 23
88Gets past futility analysis, SOPHIA trial.scaram(o)uche-January 23
87Thanks, didn't know about presentation. Looks like it may live on, subset oscaram(o)uche-January 18
86files.shareholder.com <Phase 1b/2 Study of Margetuximab Plus Pembrolizumab iMiljenko Zuanic-January 18
85K-224 preliminary results in abstract: abstracts.asco.org On many occasion (HMiljenko Zuanic-January 16
84Bullish crossover in Stochastic oscillator and RSI(14) stands at 62.81 with posiAlejandroo Green-January 15
83Presentation wassssss....zzzzzzzzzMiljenko Zuanic1January 11
82MGNX flat for last 12 months. Can S. Koeing bring some light at JPM18 (4w schedMiljenko Zuanic-January 11
81ir.macrogenics.com Are Genentech R&D machineries slowing down? Maybe MGNXMiljenko Zuanic-January 4
80Thanks, Miljenko (eom).DewDiligence_on_SI-January 2
79Well, at this point we know Opdivo/Keytruda activity (limited, but small improveMiljenko Zuanic-January 2
78Outcome of this trial will set stage for ALL new PD-1 inhibitors/candidates. PleDewDiligence_on_SI-January 2
77seekingalpha.com Outcome of this trial will set stage for ALL new PD-1 inhibitorMiljenko Zuanic-January 2
76OT TRIL call: thx, but not yet to a level where put sales are interesting. Watctuck-11/9/2017
75nice call! (not enjoying it at all! ;-)scaram(o)uche-11/9/2017
74Thanks!scaram(o)uche-11/8/2017
73<I am interested in knowing if 012 contributed the variable region to MGD013.Miljenko Zuanic111/8/2017
72We were all surprised by the size of the 012 deal. I'm not going to try to scaram(o)uche-11/7/2017
71>> I could easily see it coming back some. << I could easily see a scaram(o)uche-11/7/2017
70>> saying folks who sold a few weeks ago are now chasing TRIL stock into bscaram(o)uche-11/7/2017
69Partially OT >>Have you considered that seller's remorse could be extuck-11/7/2017
68>> SITC in general seems be getting regarded as something of a bust, wrt tscaram(o)uche-11/7/2017
67MGA012 at SITC (so far, just the dose escalation phase data): >>A phase tuck-11/7/2017
66Two months in, I'm just pleased that the first patients dosed (a presumptionscaram(o)uche-10/25/2017
65So, Incyte does not believe in PD-1 x LAG-3 bispecific? Why not sub-license,....Miljenko Zuanic-10/25/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.